Cefixime is used for bacterial infections recovery, Ornidazole is used as antibiotic for protozoan infections and Moxifloxacin is also an antibiotic for multiple bacterial infections. Accurate, simple and precise HPLC method was developed for the determination of Cefixime, Ornidazole and Moxifloxacin in the tablet pharmaceutical dosage form. The RP-HPLC method was developed and validated with precision, specificity, accuracy, ruggedness, robustness and linearity. Chromatographic conditions are mobile phase A: 6.8g KH2PO4 in 1000 ml water and mobile phase B: Acetonitrile, Agilent Zorbax SB-C18, 100 x 4.6mm, 5µm, 280 nm, 1.0ml/min, 25 min (gradient program: mobile phase B at 0min 5%, 5min 5%, 10 min 15%, 14 min 15%, 17 min 35%, 20 min 5% and 25 min 5%. All validation results showed the accuracy results and % RSD for test area, %assay values were also within the limits. This HPLC method can be used to analyze the regular product quality control purpose.
INTRODUCTION
Cefixime is used to treat bacterial infections includes otitis media, pneumonia, strep throat, urinary tract infections, gonorrhoea and lyme disease.
1-2 Cefixime was approved in USA IN 1989. It is marketed under many trade names such as texit (Apex, Cef-3 and Denvar. [3] [4] [5] Cefixime chemical formula is C16H15N5O7S2 and molecular mass is 453.452 g/mol. Ornidazole is used as antibiotic for some protozoan infections. [6] [7] This drug can be used for crohn's disease after bowel resection. [8] [9] [10] Moxifloxacin is an antibiotic used to treat the number of bacterial infections. 11 These infections include pneumonia 12 , conjunctivitis 13 , endocarditis 14 , tuberculosis and sinusitis. 15 Moxifloxacin was approved in the USA in 1999 and it is on the WHOs list of essential medicines. Literature survey reveals the few reported methods on Cefixime and Ornidazole on UV spectroscopy methods [16] [17] and some methods were published on HPLC. 18 Cefixime and Moxifloxacin were determined by UV spectrophotometric method [19] [20] [21] [22] and some of the authors were published on HPLC instrument.
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EXPERIMENTAL
Materials
Agilent makes alliance HPLC instrument equipped with a pump, detector, auto sampler, column oven and Empower software. Agilent makes Zorbax Eclipse SB C18 100mm column was purchased from a local distributor in Hyderabad. Analytical grade K2HPO4 buffer salt and ortho-phosphoric acid were used purchased from Merck India Pvt. Limited. Gradient grade acetonitrile and methanol were purchased from Qualigens chemical supplier from Hyderabad.
Methods
Reverse phase HPLC method was optimized to determine the Cefixime, Ornidazole and Moxifloxacin in solid dosage formulations. Optimized method was validated with precision, linearity, accuracy, limit of detection, limit of quantification, ruggedness and robustness. Chromatographic conditions were discussed below,
HPLC conditions
Column : Agilent Zorbax SB-C18, 100 x 4.6mm, 5µm Mobile Phase-A 6.8 g of di-potassium hydrogen phosphate (KH2PO4) weighed and transferred into 1000 mL of water and sonicated to dissolve. The resulting solution was degassed through a 0.45µm membrane filter using a vacuum pump.
Mobile Phase-B Gradient grade acetonitrile was used as mobile phase B and degassed through the 0.45µ filter.
Diluent
Mobile phase A and B were mixed in the ratio of 50:50 % v/v and mixed well. Standard Solution Preparation 1.0ml of the standard stock solution was pipetted and transferred into 50 ml class A volumetric flask and diluted with a diluent.
Mobile Phase Elution Gradient Program
Preparation of Cefixime and Ornidazole Sample Solution
Randomly selected 20 tablets and weighed individually and calculated the average weight of one tablet and prepared the fine powder. Equivalent to 50 mg of Cefixime and Ornidazole tablets powder was weighed and transferred into 100 mL volumetric flask. 50 ml of diluent was added and dissolve the content by using handshake and sonication for 10 minutes. Further volume was diluted with a diluent. The stock solution was filtered with Whatman filter. 1 mL of the above solution was transferred into a 50 mL volumetric flask and diluted.
Preparation of Cefixime and Moxifloxacin Sample Solution
Randomly selected 20 tablets and weighed individually and calculated the average weight of one tablet and prepared the fine powder. Equivalent to 50 mg of Cefixime and 50 mg Moxifloxacin tablets powder was weighed and transferred into 100 mL volumetric flask. 50 ml of diluent was added and dissolve the content by using handshake and sonication for 10 minutes. Further volume was diluted with a diluent. The stock solution was filtered with Whatman filter. 1 mL of the above solution was transferred into a 50 mL volumetric flask and diluted.
System Suitability Limits
All three peaks (Cefixime, Ornidazole and Moxifloxacin) in standard solution tailing factor should be not more than 2.0 and theoretical plates value should be more than 2000. %RSD for five replicate standard solutions area should be less than 2.0%.
Percentage Assay Value Calculation = Tarea X Tweight X 1 X 100 X 50 X Label claim X Potency Sarea X 100 X 50 X Sweight X 1X Tablet weight X 100 X 100
In the above calculation formula, Tarea is Peak area from sample preparation; Sarea is Average peak area from standard solution; Tweight is the weight of standard taken in mg; Sweight is the weight of the standard solution.
RESULTS AND DISCUSSION
HPLC Method Optimization
Method optimization was initiated based on the understanding of the molecules polarity, functional groups activity and reported literature. Solubility was checked in water with different pH levels, acetonitrile, methanol and mixed ratio solutions. UV spectroscopic nm was evaluated by scanning of the standard materials from 200 nm to 400 nm. Based on the evaluation of UV spectroscopic results 280 nm has a maximum absorbance at all compounds. Further, HPLC method optimization was performed. Figure-2 represented the UV spectrum of Cefixime, Ornidazole and Moxifloxacin.
HPLC Method Optimization Trial-1 Conditions 1. 1.0g of ammonium acetate in 1000 ml of water used as a buffer 2. 2. Buffer as mobile phase A and acetonitrile as mobile phase B was eluted with a gradient program 
Observation
All three peaks were eluted but Cefixime peak shape was poor. Further optimization carried out by changing the HPLC column and gradient program. Development trial mixed sample chromatogram was represented in Fig.- 
Method Validation
Optimized method was progressed for method validation as per the ICH Q2 guidance document. Precision, specificity, linearity, ruggedness, robustness and recovery studies were carried out.
System Suitability
Method system suitability was evaluated by preparing a fresh standard solution as per the finalized method mentioned in materials and method. Blank, placebo and five replicate standard solutions were injected in the HPLC system and system suitability parameters were evaluated. All system suitability results were satisfactory and all results were within the acceptable limits. Figure-9 and 10 were represented the blank and placebo. Blank and standard overlay chromatogram were represented in Fig.-11 . Figure-12 represented the placebo and standard chromatogram. Figure-13 represented the standard solution chromatogram. All five replicate standard solution chromatogram was represented in Fig.-14 . Figure- 15 to 17 were represented the peak purity plot for Cefixime, Ornidazole and Moxifloxacin. Table-2 represented the system suitability results. 
Specificity
Specificity was performed to check the interference from blank, placebo, degradation studies. Acid, base, peroxide, thermal, UV and water stress study conditions were performed. Stress study conditions were listed in Table- Linearity Linearity was performed with freshly prepared different linearity level solutions. 50%, 75%, 100%, 125% and 150% linearity solutions were prepared and performed the linearity as per the ICH Q2 guidance documents. Figure-32 has represented the linearity overlay chromatograms. Figure-33 to 35 were represented the linearity graphs for Cefixime, Ornidazole, Moxifloxacin. Table-7 represented the linearity results. 
